BidaskClub Lowers VBI Vaccines (VBIV) to Sell

VBI Vaccines (NASDAQ:VBIV) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. BMO Capital Markets assumed coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price objective on the stock. Finally, Canaccord Genuity assumed coverage on VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $8.75.

Shares of VBI Vaccines (VBIV) opened at $4.19 on Friday. VBI Vaccines has a one year low of $3.04 and a one year high of $6.60. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03. The firm has a market capitalization of $264.15, a PE ratio of -5.74 and a beta of 1.75.

VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.01). VBI Vaccines had a negative return on equity of 49.17% and a negative net margin of 4,463.06%. equities research analysts anticipate that VBI Vaccines will post -0.9 earnings per share for the current fiscal year.

In related news, major shareholder Life Sciences Maste Perceptive acquired 3,100,000 shares of the business’s stock in a transaction that occurred on Thursday, October 26th. The shares were acquired at an average cost of $3.05 per share, with a total value of $9,455,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeff Baxter acquired 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $71,250.00. Following the completion of the purchase, the chief executive officer now directly owns 135,255 shares in the company, valued at approximately $642,461.25. The disclosure for this purchase can be found here. Insiders purchased a total of 4,080,738 shares of company stock worth $12,480,151 over the last three months. 54.50% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in shares of VBI Vaccines in the 2nd quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. bought a new position in shares of VBI Vaccines in the 2nd quarter valued at approximately $187,000. Bank of New York Mellon Corp acquired a new stake in VBI Vaccines in the 2nd quarter valued at approximately $193,000. Teachers Advisors LLC acquired a new stake in VBI Vaccines in the 2nd quarter valued at approximately $195,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in VBI Vaccines in the 2nd quarter valued at approximately $262,000. 20.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/20/bidaskclub-lowers-vbi-vaccines-vbiv-to-sell-2.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply